[Beta-receptor blockaders in the prevention of hemorrhaging of esophageal varices?].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004932:Esophageal and Gastric Varices / Q000150:complications*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D009248:Nadolol / Q000627:therapeutic use; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000008:administration & dosage
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D012597:Sclerosing Solutions; D009248:Nadolol; D011433:Propranolol; D008790:Metoprolol
Beta-Rezeptorenblocker zur Prophylaxe der Osophagusvarizenblutung?